Fisher Asset Management LLC Sells 106,543 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Fisher Asset Management LLC trimmed its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 13.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 710,876 shares of the biopharmaceutical company’s stock after selling 106,543 shares during the quarter. Fisher Asset Management LLC owned about 1.27% of Agios Pharmaceuticals worth $15,831,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Armistice Capital LLC increased its holdings in shares of Agios Pharmaceuticals by 2.1% during the third quarter. Armistice Capital LLC now owns 3,324,000 shares of the biopharmaceutical company’s stock worth $82,269,000 after purchasing an additional 68,000 shares during the period. Rock Springs Capital Management LP increased its stake in Agios Pharmaceuticals by 0.9% during the 3rd quarter. Rock Springs Capital Management LP now owns 2,710,061 shares of the biopharmaceutical company’s stock worth $67,074,000 after acquiring an additional 23,894 shares during the period. Deutsche Bank AG raised its holdings in Agios Pharmaceuticals by 0.6% in the 3rd quarter. Deutsche Bank AG now owns 581,601 shares of the biopharmaceutical company’s stock valued at $14,395,000 after acquiring an additional 3,626 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Agios Pharmaceuticals by 3.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 451,695 shares of the biopharmaceutical company’s stock valued at $11,179,000 after acquiring an additional 14,420 shares during the period. Finally, Hudson Bay Capital Management LP lifted its position in shares of Agios Pharmaceuticals by 3.8% during the 3rd quarter. Hudson Bay Capital Management LP now owns 270,000 shares of the biopharmaceutical company’s stock valued at $6,682,000 after acquiring an additional 10,000 shares during the period.

Analyst Ratings Changes

A number of research analysts recently commented on AGIO shares. JPMorgan Chase & Co. dropped their price target on Agios Pharmaceuticals from $31.00 to $30.00 and set a “neutral” rating for the company in a research note on Friday, February 23rd. Royal Bank of Canada dropped their target price on shares of Agios Pharmaceuticals from $43.00 to $42.00 and set an “outperform” rating for the company in a research report on Friday, February 16th. The Goldman Sachs Group increased their price target on shares of Agios Pharmaceuticals from $29.00 to $33.00 and gave the stock a “neutral” rating in a research report on Friday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, April 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $35.00.

Insider Transactions at Agios Pharmaceuticals

In related news, insider James William Burns sold 2,642 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $32.57, for a total transaction of $86,049.94. Following the sale, the insider now owns 34,518 shares of the company’s stock, valued at approximately $1,124,251.26. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, insider James William Burns sold 2,642 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total value of $86,049.94. Following the completion of the transaction, the insider now owns 34,518 shares in the company, valued at approximately $1,124,251.26. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Brian Goff sold 4,156 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $32.57, for a total transaction of $135,360.92. Following the sale, the chief executive officer now owns 53,780 shares in the company, valued at $1,751,614.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,035 shares of company stock worth $475,277. Corporate insiders own 4.24% of the company’s stock.

Agios Pharmaceuticals Trading Down 0.1 %

Shares of NASDAQ AGIO opened at $34.54 on Monday. The company has a market cap of $1.96 billion, a price-to-earnings ratio of -5.47 and a beta of 0.81. Agios Pharmaceuticals, Inc. has a 12 month low of $19.80 and a 12 month high of $35.50. The stock has a 50-day moving average price of $30.61 and a two-hundred day moving average price of $25.68.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.64) by $0.19. The business had revenue of $8.19 million during the quarter, compared to analysts’ expectations of $8.37 million. Agios Pharmaceuticals had a negative net margin of 1,199.26% and a negative return on equity of 39.74%. The firm’s quarterly revenue was up 46.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.47) EPS. On average, sell-side analysts predict that Agios Pharmaceuticals, Inc. will post -5.27 earnings per share for the current year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.